Exclusive: J&J looking at new multiple myeloma drug launch next year

US health care giant Johnson & Johnson (NYSE: JNJ) is set to launch its drug to treat multiple myeloma in 2016, pending regulatory approvals, Peter Lebowitz, head of global oncology, Janssen Pharmaceutical Companies of Johnson & Johnson, told The Pharma Letter in an interview at a London event.

Daratumumab, an investigational anti-cancer drug is currently under review by the US Food and Drug Administration. The regulator has granted the drug candidate priority review for the indication to treat multiple myeloma.

“The Daratumumab submission has gone to the FDA as well as the European regulators, so we are hoping that one comes along quickly,” said Mr Lebowitz.